Bellecapital International Ltd. Has $9.27 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Bellecapital International Ltd. raised its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 7.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 56,877 shares of the company's stock after buying an additional 3,800 shares during the quarter. Zoetis accounts for 1.6% of Bellecapital International Ltd.'s portfolio, making the stock its 21st largest position. Bellecapital International Ltd.'s holdings in Zoetis were worth $9,267,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Hancock Whitney Corp boosted its position in Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company's stock worth $3,628,000 after acquiring an additional 61 shares during the period. Strategy Asset Managers LLC boosted its holdings in shares of Zoetis by 3.5% during the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company's stock worth $356,000 after purchasing an additional 62 shares during the period. VeraBank N.A. grew its position in Zoetis by 4.1% during the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company's stock valued at $254,000 after purchasing an additional 62 shares in the last quarter. Procyon Advisors LLC grew its position in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after purchasing an additional 63 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators increased its stake in Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after buying an additional 65 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Zoetis stock traded down $2.94 on Wednesday, reaching $166.96. 3,666,720 shares of the stock were exchanged, compared to its average volume of 3,280,356. The stock has a market cap of $74.76 billion, a PE ratio of 30.52, a PEG ratio of 2.78 and a beta of 0.94. The firm has a fifty day moving average price of $166.53 and a two-hundred day moving average price of $177.06. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is currently 36.56%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on ZTS. Morgan Stanley lowered their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Barclays boosted their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price target for the company. Finally, Piper Sandler increased their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.